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Prostate cancer (PrCa) is the second most common malignancy in men1. More than 50% of 
advanced prostate cancers display the TMPRSS2-ERG fusion2. Despite extensive cancer 
genome/transcriptome2-4 and phosphoproteome5 data, little is known about the impact of 
mutations and altered transcription on regulatory networks in the PrCa of individual patients. 
Using patient-matched normal and tumor samples, we established somatic variations and 
differential transcriptome profiles of primary ERG-positive prostate cancers. Integration of 
protein-protein interaction and gene-regulatory network databases6,7 defined highly diverse 
patient-specific network alterations. We found that different components of a given 
regulatory pathway were altered by novel and known mutations and/or aberrant gene 
expression, including deregulated ERG targets, such that different sets of pathways were 
altered in each individual PrCa. In a given PrCa, several deregulated pathways share common 
factors, predicting synergistic effects on cancer progression. Our integrated analysis provides 
a paradigm to identify key deregulated factors within regulatory networks to guide 
personalized therapies.   
  
 
The mutational landscapes of primary and advanced/metastatic PrCa have been extensively 
analyzed2,3,8,9, as has been the prevalence of the androgen-sensitive TMPRSS2 promoter fusion 
with ETS transcription factors10, which endows ETS with responsiveness to the androgen 
receptor (AR) that is frequently overexpressed in antiandrogen-resistant PrCa11. Recurrent 
mutations have been found in genes coding for factors regulating a plethora of pathways and 
key cellular functions, such as the androgen receptor signaling, PI3K/RAS/RAF/WNT pathways, 
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and factors involved in DNA repair and chromatin methylation, or cell cycle control. One of the 
caveats in all these studies was that, with a few exceptions9,12, information was generally 
compiled from large numbers of tumors from different patients. Thus, while enabling 
identification of predominant mutations, these studies did not reveal the spectrum of 
aberrations that existed in individual patients' prostates at diagnosis. All these aberrations may 
affect different regulatory pathways and their added, possibly synergistic action may be critical 
for malignancy and tumor progression. Indeed, restoring a normal state will require the 
correction of a highly complex and dynamically regulated system of interactive multi-
component networks which are deregulated in disease13. Towards this goal, the identification 
of aberrant networks and their inherent hierarchies is essential to design patient-selective 
therapeutic interventions through generic or key factor-specific modulation of the affected 
pathways.  
We chose prostate cancer as a solid tumor paradigm to integrate patient-specific differential 
expressed (DEGs) and mutated genes, using information from protein-protein interaction and 
gene-regulatory network databases6,7 (Fig. 1a) to generate patient-specific cancer-modified 
networks. Extensively characterized normal and tumor frozen punch biopsies from the same 
prostate were obtained from radical prostatectomy specimens of non-treated patients. 15 
primary ERG-positive tumors (T) and matched normal tissue (N) were selected by expert 
pathologists on the basis that consecutive sections of the same biopsy differed only minimally 
in tumor cellularity (>80% tumor cells), while the sections of N biopsies from the same prostate 
had 0% tumor cells. With one exception of patient 14 (P14), the proportion of infiltrating 
lymphocytes relative to tumor cells was close to 0%, only occasionally rare scattered 
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lymphocytes were observed in the stroma. The tumor sections of P14 showed up to 25% (area-
based) mononuclear immune cells. Immunohistochemistry and RNA-seq confirmed ERG 
overexpression relative to the matched N samples and all samples revealed increased androgen 
receptor (AR) levels (Fig. 1b, c).  
Whole-exome sequencing (WES, Supplementary Table 1) and subsequent calling of variants by 
MuTect2 revealed between 49 and 114 mutations in each cancer relative to the corresponding 
normal prostate tissue; only mutations predicted to have high or moderate impact were 
considered subsequently (Supplementary File 1). Intriguingly, in addition to classical mutations, 
for example in MYC, TP53, PTEN or components of the PI3K and WNT pathways2,9,14,  
unreported patient-specific mutations were observed in all samples (Supplementary Table 2; 
for validations see Extended Data Fig. 1). In P1 three hitherto unreported somatic mutations 
affected the putative tumor suppressors BANP15, FEZ116,17 (Fig. 1d) and TINAGL1, which 
interferes with both integrin and EGFR signaling18. We also found novel mutations in MAPK7 
(R400H) in P9, Annexin A1 (ANXA1, frameshift deletion; P11) and a TET2 mutation that 
truncates the protein and renders it non-functional (Fig. 1d; P14). These novel somatic 
mutations were seen only in single patients. However, the nature of the mutations, often 
truncating proteins of functional importance, is likely to have a significant impact in the 
individual case. Indeed, the ability of TINAGL1 to inhibit progression and metastasis of triple-
negative breast cancer18, provides strong rational for such personalized genomic analysis. Our 
data underscores the recent notion that “significantly mutated genes” in PrCa may occur 
frequencies of only a few percent19.  
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Mutations in regulatory elements (e.g., enhancers) and factors (e.g., transcription factors, 
epigenetic modulators, enzymes) can affect a plethora of pathways. To integrate these effects 
in the network analysis, we performed duplicate high-throughput strand-specific paired-end 
total RNA sequencing after ribosomal RNA depletion from matched T and N biopsy sections. As 
expected, T vs. N analysis of the RNA-seq datasets identified tumor-specific differentially 
expressed genes (TS-DEGs; Supplementary File 2) with diverse functionalities, comprising (i) 
cancer-specific deregulated proto-oncogenes like c-MYC (all except P6, P11, P13) but also (ii) 
pleiotropic factors like the serine protease KLK4 (P4, P10, P14, P15), a regulator of AR and the 
PI3K/AKT/mTOR pathway20 and of protease-activated receptors21. Notably, deletion of KLK4 
impairs PrCa growth20. Moreover, (iii) epigenetic modifiers like JMJD6 (P14), KDM4B (P5), 
KDM6A (P2, P8), KDM6B (P6, P9), TET3 (P12, P14), KAT2A (P3), KAT6A (P2) or HDAC9 (P2-5, P7-
11, P13-15) were differentially expressed in certain tumors. In addition to protein-coding genes, 
also the expression of (iv) certain regulatory RNAs was altered in tumors [micro-RNAs (miRs), as 
well as long non-coding RNA (lncRNAs); for annotated miRs and lncRNAs, see Supplementary 
Table 3]. Of note, the p53-inducible lncRNA NEAT, a promising therapeutic target whose 
ablation generates synthetic lethality with chemotherapy and p53 reactivation therapy22,23, was 
over-expressed in 7/15 PrCa samples. A prominent ERG binding site in VCaP and in normal 
prostate epithelial RWPE-1 cells about 4.6kb upstream of the NEAT transcriptional start site 
may account for this deregulation (see Methods). The androgen-responsive lncRNA ARLNC124 
was up-regulated in 9/15 paired samples but down-regulated in P5. HOTTIP, a component of 
H3K4 methyltransferase complexes25 that can act as AR co-activator26 and was reported as 
negatively androgen-regulated lncRNA24 in prostate cancer cells, was downregulated in 9/15 
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PrCa samples. This included several, but not all of those with up-regulated ARLNC1. A similar 
divergence was seen with putative tumor suppressor and oncogenic miRNAs that are actively 
considered for clinical development27. For example, the RNA levels of tumor-suppressor miR34a 
were decreased in three samples (P10, P13 and P15) but increased in P4 and not affected in 11 
other samples. MiR222, which displays targetable oncoMir characteristics in liver, pancreas and 
lung tumors27,28, was unexpectedly down-regulated in 8/15 PrCa samples. Together, these 
vastly divergent genetic mutations and altered, often counter-intuitive gene expression 
patterns revealed the need to decipher for each individual patient the complexity of the 
deregulated systems to identify key targets in critical signaling pathways and/or key nodes in 
(sub)networks for concomitant intervention at several functionally different levels to generate 
synergistic effects.  
As a first step towards the integration of the various deregulated functions within each tumor, 
we performed a patient-centered pathways enrichment analysis for TS-DEGs using Panther29 in 
the GenCodis3 environment30. While this analysis revealed several pathways commonly 
deregulated in PrCa of several patients - particularly cadherin, Wnt and integrin signaling - it 
also demonstrated that in each patient different sets of pathways were deregulated. Indeed, P5 
and P6 had, respectively, the most and least severely affected PrCa in terms of numbers of 
deregulated pathways (Fig. 2; Extended Data Fig. 2 shows additional 52 patients from the TCGA 
repository). Moreover, different numbers and components of a commonly deregulated 
pathway were altered in different patients, yielding different p-values. As pointed out 
previously14, while genetic mutations of core Wnt pathway components are rare in PrCa, 
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abnormal expression of −catenin is frequent, suggesting that this deregulation occurs 
indirectly.  
Genes never function in isolation but rather in a highly complex physiological context, which 
can be illustrated by their "communication" with other cellular components. To gain a more 
precise insight into the altered "communication" by patient-specific gene deregulations and 
mutations, we re-constructed "master networks" from all deregulated for each prostate cancer 
by integrating the connectivities provided by the STRING protein-protein and CellNet 
transcription factor-target gene interaction databases; in addition, we integrated all mutated 
genes and identified putative ERG and AR target genes by cognate binding sites in the vicinity of 
the transcriptional start site (TSS) [see Methods; Supplementary File 3 (cytoscape masterfile for 
each patient)]. Within these master networks, we studied first the components of the canonical 
and non-canonical Wnt pathways by merging all 183 deregulated/mutated genes of 15 patients 
(Extended Data Fig. 3a). Displaying the affected components in color in the context of the entire 
Wnt pathway connectivity revealed an unexpected heterogeneity (Fig. 3, Extended Data Fig. 3b-
l). In P2 (Fig. 3a) an important signaling factor (phospholipase PLCB1) for the production of 
second messenger molecules (DAG, IP3) is mutated in the phospholipase domain (V571M) and 
the expression of multiple other master genes is deregulated, including PPP3CA, GSK3B, MYC, 
TP53, HDAC1 in addition to several WNT and Frizzled (FZD) receptor genes. Notably, ChIP-seq 
data of TMPRSS2-ERG positive VCaP and normal RWPE1 prostate epithelial cells indicate that 
WNT7B and HDAC1 are putative dual AR and ERG target genes, most likely affected by 
deregulated ERG and possibly, AR signaling (Extended Data Fig. 4a, b). Even more strikingly, the 
genes of several key signaling factors (PAK1, CREM) and of the epigenetic modulator SMARCD3 
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have apparently acquired ERG binding capability in their promoter regions during tumorigenesis 
(for SMARCC1, see Extended Data Fig. 4c), as it was reported for the ERG-mediated repression 
of checkpoint kinase 131. In contrast, P6 showed a very small number of deregulated 
components of the core Wnt pathway (Fig. 3b), comprising three upregulated FZD receptors 
along with the cognate WNT2B ligand and WNT2 which acquired ERG binding near the TSS in 
VCaP cells (Extended Data Fig. 4c, e). While such a scenario may be addressed with WNT 
inhibitor-based therapeutics, the diversity of deregulated Wnt networks in different patients 
may explain why the notion that targeting high Wnt--catenin signaling in cancer would be 
universally beneficial has been called into question32. P9 and P10 revealed two other scenarios 
of individual network alterations (Fig. 3c, d). Such patient-specific network alteration was also 
seen for less frequently affected signaling pathways. The PDGF and EGFR pathways were 
affected seriously in 10 and 7 patients, respectively (Fig. 4a, e; merged networks of alterations). 
However, the scenarios were completely different across individual patients (Fig. 4; Extended 
Data Fig. 5).  Important changes were seen in P4 and P5 (Fig. 4b, c) but hardly any in P13 (Fig. 
4d). The same was true for alterations of the EGFR pathway in P5 and P15 (Fig. 4f, g), while 
much less nodes were affected in P8 (Fig. 4h).  
Finally, given that pathways do not act in isolation, we extracted the affected components of 
several pathways from the "master networks". This analysis showed very clearly that, for P2 
and P5 several genes of the Wnt, cadherin and integrin pathways, are shared between two or 
even three pathways (Fig. 5); the same was observed for other combinations of pathways 
(Extended Data Fig. 6). The functional consequence of deregulation/mutation of such genes is 
predicted to be serious and such nodes may comprise candidates for therapeutic targeting. It is 
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worth pointing out that also genes at the nexus of several pathways diverged from one patient 
to another, as shown for P2 and P10 (Fig. 5a, b). Indeed, a hypothetical treatment of these two 
patients - assuming that drugs targeting key components would be available - will have to 
consider very different scenarios. In the PrCa of P2, common to two or all three pathways, 
there is a strong upregulation of the expression of several WNT and FZD genes, as well as 
GSK3B and LEF1. All these factors are potentially druggable and clinical trials are pursued at 
various levels. In addition, these genes are functionally connected with important other 
upregulated genes of the Wnt-pathway, such as TP53, MYC, HDAC1 or PPP3CA. For P10, only 
two FZD genes are overexpressed in cancer and all deregulated WNT genes are less expressed 
than in the normal prostate tissue of this patient. Moreover, HDAC1 is mutated and MYC is 
rather repressed. On the other hand, RANBP2 is uniquely overexpressed in P10. Given its multi-
functional role as E3-SUMO protein ligase, its overexpression may be an important component 
of the deregulated network.  
Taken together, the patient-centered network analysis we describe here for TMPRSS2-ERG 
positive primary prostate cancer reveals very divergent patient-specific deregulated and 
mutated genomic landscapes. This supports a rationale in which therapeutic options are 
considered in the context of a personalized integrative functional genomics analysis.  
In the present case, the affected organs have been surgically removed and with one exception, 
all patients are still alive. However, we conducted this study as paradigm for other solid cancers 
where surgery is not possible and for monitoring the development of resistance during therapy. 
In addition, there is a growing importance of single cell functional genomics done with 
circulating tumor cells for diagnosis. Ultimately, additional dimensions, such as chromatin 
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accessibility or RNA regulators such as the newly described circular RNAs33,34, as well as 
metabolomic changes, may be integrated in this analysis to reveal what communication 
networks are at the origin, maintenance and progression of the disease and which regulatory 
circuits can be modulated for therapeutic purposes, including escape from resistance to 
therapy.   
 
Online Content 
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Reprints and permissions information is available at ... 
Correspondence and request for materials should be addressed to H.G. 
 
Figure Legends 
Fig. 1: Analysis strategy and characterization of patient-matched samples. a, Sketch of the 
workflow of this study. b, Representative IHC images of cancer and corresponding matched 
normal samples from patient 15 stained with an anti-AR antibody (top panel) or an anti-ERG 
antibody (bottom panel). c, RNA-seq data of ERG expression in all the patients’ tumors relative 
to their matched normal. Differential ERG expression for all patient-matched duplicate samples 
was supported by q value < 10-69 using DEseq (see Methods for details). d, Schematic illustration 
of 4 novel mutations in P1, P9, P11 and P14, which are predicted to have a high or moderate 
impact. 
 
Fig. 2: Divergence of pathways and severity of pathway alteration in individual prostate 
cancer patients. Pathways predicted by Panther to be significantly enriched in patient-specific 
DEGs are shown on the left of the table while patient identification numbers are given at the 
bottom. Panther-computed p-values for the deregulation of a given pathway are illustrated as 
blue-to-red color-coded rectangles; grey color indicated no significant alteration. Numbers in 
the rectangles give the mutated and deregulated genes for each pathway and patient 
(mutated/DEG; see Methods for details). 
All rights reserved. No reuse allowed without permission. 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/695999doi: bioRxiv preprint first posted online Jul. 11, 2019; 
 16 
 
Fig. 3: Patient-specific aberrations of the Wnt network are highly divergent. Global networks 
were established from differentially expressed genes (DEGs, >2-fold) in duplicate patient-
matched tumor vs. normal samples by integrating the connectivities provided by STRING 
(protein-protein interaction database) and CellNet (transcription factor-target gene 
interactions); this integration yielded a 'master network' of DEGs for each patient, revealing the 
connectivities between deregulated genes. The DEG master network of each patient was 
complemented by the mutations of predicted high and moderate impact, and the components 
of the canonical and non-canonical Wnt pathways were extracted. DEGs and mutated genes are 
depicted in color for a, P2, b, P6, c, P9 and d, P10 in the background (grey nodes and 
connectivities) of all merged components of the Wnt pathways that are deregulated or mutated 
in all 15 patients (Suppl. Fig. 3a). The corresponding deregulated networks of the other patients 
are shown in Suppl. Fig. 3b-l). When known, connectivities are displayed as green (activation) or 
red (inhibition) lines; unknown connectivities and protein-protein interactions they are 
displayed as grey lines. DEG specifics and mutations are color-coded as describe below the 
figure.  
 
Fig. 4: Divergent alterations of the PDGF and EGFR signaling networks in each patient. Ten 
patient exhibited serious aberrations in the PDGF and 7 patients in the EGFR signaling 
networks. a, Merged network of alterations (DEG, mutation) in the PDGF and e, EGFR networks. 
Using this merged network as background (grey nodes and connectivities) the aberrations in 
each individual patient are depicted in color. b, c, Patients with heavily (P4, P5) or d, minimally 
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(P13) affected PDGF networks. f, g, Patients with heavily (P5, P15) or h, minimally (P8) affected 
EGFR networks. Color codes are displayed below the figure and in the legend to Fig. 3. 
 
Fig. 5: Affected signaling network crosstalk divergently between each other in each patient. a, 
Illustration of the merged networks of the affected genes from the Wnt, Cadherin and Integrin 
signaling pathways in the prostate of P2 revealing that several of the DEGs are common to 
different pathways. b, Illustration as in a but for P10. Color codes are displayed below the figure 
and in the legend to Fig. 3. 
 
 
Extended Data Fig. 1: Validation of four selected different types of mutations from Exome-seq 
analysis using PCR coupled to Sanger sequencing. a, Single base deletion in MGA gene in 
patient 5. b, Single base insertion in CFTR in patient 12. c, Missense mutation in MST1R in 
patient 14 and d, Point mutation in RASSF8 in patient 13. Red ovals highlight the regions of the 
mutations. Original (color-coded at the top) and mutated sequences are depicted below each 
sequence for comparison.  
 
Extended Data Fig. 2: Heatmap showing enriched pathways using gene expression data from 
TCGA for prostate cancer. Note that we selected only datasets for which PrCa with patient-
matched normal tissue were available. P-values corresponding to PANTHER-predicted 
alteration of pathway (left) are shown in color code (scale is shown on the right of the table). 
TCGA codes for patients are given at the bottom.   
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Extended Data Fig. 3: Patient-specific deregulations of Wnt pathway components for the 
indicated patients (P). a, Merged network of all 15 patients used a background in (b) to (l). 
Frame and color codes are shown below P5. b to l, deregulated and/or mutated components of 
the Wnt pathway in each patient. 
 
Extended Data Fig. 4: AR binding and acquisition of ERG binding sites in VCaP prostate cancer 
cells relative to RWPE-1 prostate epithelial cells. Screenshots of qcGenomics (http://www.ngs-
qc.org/qcgenomics/) browser NAVi displaying genes that show AR and/or ERG binding in their 
promoter regions. a, HDAC1; b, WNT7B; c, SMARCCl; d, WNT2; e, FDZ8. ChlP-seq data sets in a 
and b are from GEO accession numbers (from top to bottom) GSM2058880 (AR, VCaP), 
GSM1328978 (ERG, VCaP) and GSM927071 (ERG, RWPE-1), as specified. Note that in (a) ERG 
binding at the HDAC1 promoter is seen in VCaP and RWPE-1 cells, while in (b) for WNT7B a 
promoter-proximal ERG binding is seen in ‘normal’ RWPE-1 but not in VCaP cells; this ERG 
binding site is distant from the AR binding site. The ERG ChlP-seq data sets in c, d and e are 
from GEO accession numbers (from top to bottom) GSM927071 for RWPE-1, GSM1328978 for 
VCaP (both use anti-ERG antibody Epitomics 2805-1), GSM2195110 for RWPE-1 and 
GSM2086313 for VCaP. GSM2195110 was done by using Anti-ERG Clone 9FY Biocare # CM421 
C, GSM2195110 used an anti-ERG antibody but did not provide the source. Note the 
consistency between corresponding experiments with different antibodies.  
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Extended Data Fig. 5: Patient-specific deregulations of the PDGF and EGFR pathway 
components for the indicated patients (P). a, Merged network of 10 patients used a 
background in (b) to (l) for PDGF pathway. j, Merged network of 7 patients used as a 
background in (k) to (o) for EGFR pathway. Frame and color codes are shown below P12. b to i, 
deregulated and/or mutated components of the PDGF pathway in each patient. k to o 
deregulated and/or mutated components of EGFR pathway in each patient. 
 
Extended Data Fig. 6: Patient-specific deregulations of the PDGF and EGFR pathway 
components for the indicated patients (P). a, Network display of deregulated and mutated 
factors of patient P1 in the WNT, Angiogenesis and Cytokine Pathways to reveal connectivities 
between the different pathways. b, Similar representation of the de-regulated and mutated 
factors in P2 for the WNT, PDGF and EGFR pathways.  
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Methods 
Patient sample collection. Samples from non-treated patients were obtained after informed 
consent in accordance with the Declaration of Helsinki and stored at the « CRB Cancer des 
Hôpitaux de Toulouse (BB-0033-00014) » collection. According to the French law, CRB Cancer 
collection has been declared to the Ministry of Higher Education and Research (DC-2008-
463) and obtained a transfer agreement (AC-2013-1955) after approbation by ethical 
committees. Clinical and biological annotations of the samples have been declared to the CNIL 
(Commission Nationale de l’Informatique et des Libertés). All samples were collected within 15 
minutes after radical prostatectomy to shorten the delay between de-
vascularization and freezing, and to ensure preservation of labile molecules. Immediately 
following prostatectomy, punch biopsies ("carrots") of 8mm diameter were taken from tumor 
and adjacent normal tissue, snap frozen in liquid nitrogen and stored at -80 ° C. Carrots used for 
genomic and transcriptomic studies were cut into sequentially tissue sections and the tumor 
cellularity was monitored at regular intervals by histological staining to ensure homogeneity of 
tumor and normal sections stored in LoBind tubes at -80°C.  
 
Tissue microarrays. Tissues microarrays (TMA) were made from paraffin-embedded tissue 
cores of histopathologically-confirmed prostate cancer and patient-matched tumor-adjacent 
normal tissue. For each tumor, two representative tumor areas were selected and two cores of 
2 mm in diameter were punched and included in paraffin recipient blocs. Two adjacent normal 
tissues of each selected prostatic sample were arrayed on TMAs and constituted the "normal" 
counterparts of each tumor sample. The TMAs were performed on the histopathology platform 
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of the Biological Resource Center (CRB) Cancer of the Toulouse University Hospital, in a semi-
automated way using the EZ-TMA™ Manual Tissue Microarray Kit, IHCWORLD. The slides were 
examined by HE coloration and immunohistochemical studies were performed on TMA tissues. 
Immunohistochemistry was done using an automated Dako Autostainer. The following 
antibodies were used: ERG (Epitomics, EPR3864, dilution 1/100, pH 6), EZH2 (Novocastra, NCL-
L-EZH2, 1/50, pH 9); Androgen Receptor (Dako, M3562, 1/200, pH 9). Slides were digitalized 
using a Hamamatsu NanoZoomer slide scanner (Japan) at 20x magnification with a resolution of 
0.46 microns per pixel.  The results were interpreted under an optical microscope by two 
pathologists (CM and M-LQ), blinded to the clinical data. 
 
Whole exome sequencing (WES) and analysis pipeline. For WES, DNA was isolated from frozen 
tumor and matched normal tissue using QIAamp DNA micro kit (Cat No.56304 Qiagen) 
according to manufacturer’s instructions. DNA was processed by GATC Biotech for exome 
capture, library preparation and sequencing. Briefly, SureSelectXT Human all exon V6 kit 
(Agilent Technologies) was used to capture exons, libraries were prepared using TruSeq DNA 
library preparation kit (Illumina inc) according to manufacturer’s instruction and Paired-End 
125-base sequencing was performed on Illumina HiSeq 2000. FastQ files provided by GATC 
Biotech were processed for variant discovery with Genome Analysis Toolkit (GATK, 3.7)35 using 
default parameters. 
To assist in WES analysis we developed a WES Analysis Pipeline [written in Python3 with the 
Snakemake (3.13.3)36 management tool] and used the Genome Analysis Toolkit (GATK, 3.7)35 
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according to the authors' instructions (download access in Supplementary Information). The 
following tools were used for each step in the pipeline:  
Pre-processing of the samples. FastQ files were first aligned to hg19 
(https://drive.google.com/open?id=1EuPivu7Quj5XiJlojpIxIREmyb4y3NCW, Genome Reference 
Consortium Human Build 37)  using BWA-mem (0.7.17)37  using standard parameters. The 
output SAM files were then converted to BAM files using SAMtools (1.6)38. BAM files were 
processed using Picard tools (2.14) to sort by coordinates, remove duplicates and add read 
group tags (essential to differentiate between Normal and Tumor samples) to samples before 
indexing them with SAMtools. Then BAM files were recalibrated (BQSR) using GATK, as 
recommended for enhancing variant calling 
(https://gatkforums.broadinstitute.org/gatk/discussion/44/base-quality-score-recalibration-
bqsr) by providing databases of known polymorphic sites: a set of curated INDEL entries 
(Mills_and_1000G_gold_standard.indels.hg19.sites.vcf, 
https://drive.google.com/open?id=1tXzEFrydWBzxWoP1iQS8QuYrXW2x75TU), a Single 
Nucleotide Polymorphism database dbSNP (dbsnp_138.hg19.vcf, 
https://drive.google.com/open?id=1d8OfwtB7zW8Tl27YxuFIF8eSkj3AgP_r), the COSMIC 
database of somatic cancer mutations (CosmicCodingMuts_GHCr37.p13.vcf, 
https://drive.google.com/open?id=1tXzEFrydWBzxWoP1iQS8QuYrXW2x75TU). Creating the 
Panel of Normals (PON). The 'Panel of Normals' is created from the normal samples using GATK. 
This method is used as a filter to reject artifacts and germline variants that are present in at 
least two normal samples (-minN 2). It uses as input the hg19, the dbSNP, the COSMIC and the 
intervals of the genome to analyze only the exons of all genes captured (HumanAllExonV6r2, 
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https://drive.google.com/open?id=1rxCn7x4SWAg9r8bYAmDzBV-8en-f8KLa). It generates a 
new file (https://drive.google.com/open?id=1MGuJYBTlzAUFKD0WfiEGwiU3MXUHgHpf) that 
will be used when calling the variants. Variant calling with MuTect2. After pre-processing and 
alignment, MuTect2 (GATK) was used to call somatic variants39. Inputs are the following files: 
hg19, PON, HumanAllExonV6r2, COSMIC and dbSNP. The normal and tumor samples were 
compared using the following parameters: pir_mad_threshold: 6; 
max_alt_alleles_in_normal_count: 5; pir_median_threshold: 35; 
standard_min_confidence_threshold_for_calling: 30. Annotation of VCF. The annotations of the 
VCF files were done using SnpEFF40 and SnpSift40 with hg19 as reference genome. 
Validation of mutations. Target regions were amplified by PCR. PCR products were purified 
using Qiagen gel extraction kit (28704) and sequenced by Eurofins Genomics using the BigDye 
Terminator Cycle Sequencing Kit and an ABI 3730xl automated sequencer (Applied Biosystems). 
The sequencing primers were the same as those used for PCR amplification. Variants were 
confirmed using SNAP gene viewer. For primer sequences, see Supplementary Information. 
RNA-sequencing. RNA was isolated from frozen tumor and matched normal tissue using Trizol 
reagent (Invitrogen). RNA was further cleaned up using RNEasy minElute RNA clean up kit 
(Qiagen). RNA was then sent to GATC Biotech (Konstanz, Germany) for strand specific, paired-
end and Ribo-minus total RNA-seq. Briefly, ribosomal RNA depletion was done using Ribo Zero 
gold kit (Illumina Inc); libraries were prepared using TruSeq stranded total RNA library prep kit 
(Illumina Inc.). Paired-end 125 base or 150 base sequencing was performed using Illumina HiSeq 
2000. FastQ files received from GATC Biotech were used for further analysis. 
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RNA-seq analysis pipeline. The analysis pipeline consists of the following steps. Pre-processing, 
alignment and counting raw reads. FastQ files were assessed for quality using FastQC. FastQ 
files were aligned to reference genome (human genome hg19) using the Hisat241 aligner. 
Aligned SAM files were converted to BAM files and sorted using SAMtools38. The R package 
SummarizedExperiment42 was used for counting raw reads per exon/gene. 
Differential gene expression analysis. The patient specific differential gene expression analysis 
was done using DESeq2 (1.20.0)43 according to the general steps described with the parameters 
given below. The samples have been analyzed by giving the matched raw read counts 
normal/tumor duplicates as input. 
− Removing sum of row counts: 0; 
− CooksCutoff: False; 
− Alpha: 0.01; 
− Subset genes with Adjusted P-value ≤ 0.01; 
− Subset genes with Log2FC ≤ -1 or Log2FC ≥ +1. 
The corresponding list of Differentially Expressed Genes (DEGs) for each patient was used for 
further analysis. 
Pathway enrichment analysis. To interpret the gene expression data, the DEG list was loaded 
into GeneCodis30 and the Panther pathway analysis function was used to retrieve enriched 
pathways. Hypergeometric correction of p-values was applied and pathways displaying a 
corrected p-value < 0.01 were considered enriched. We clustered all pathways of all samples 
using Plotly (4.8.0) (https://plot.ly/) in R. For the datasets obtained from TCGA 
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(https://portal.gdc.cancer.gov/, 54 PrCa patient data along with matched normal), HT-seq 
counts were downloaded for each patient corresponding to tumor and matched normal. 
DEseq2 was used to identify the DEGs for each patient. Pathway enrichment analysis was 
performed in as described before. 
Patient-specific network generation and visualization. To generate the gene networks for 
individual patients we extracted the list of mutated genes from WES and differentially 
expressed genes (DEGs) from RNA-seq of tumor vs normal samples for each patient. These lists 
of genes were queried against two known databases of network interactions, STRING44, a 
Protein-Protein Interaction (PPI) database, and CellNet7, a gene regulatory network (GRN) 
database. For STRING, we merged the list of genes (DEGs and Mutation, keeping the 
information whether the gene is a DEG or a mutated gene as attributes), removed any 
duplicated genes and queried them using an in-house script (Supplementary Information). As 
for the parameters, we only chose edge interactions that have been experimentally validated 
(exp_score ≠ 0). For CellNet, we queried only the differentially expressed genes on the target 
genes and retrieved along the cognate transcription factors. We chose interactions who had 
only a z-score ≥ 5. After obtaining networks from both databases, we proceed to add the 
information from WES and RNA-seq whether the genes were mutated, differential expressed or 
both, in addition to the information obtained from the databases. 
Network visualization and merging using Cytoscape. Individual networks, created by using 
Cellnet and String for each patient, were visualized using Cytoscape45. Finally, CellNet and 
STRING networks for each patient were merged using the Cytoscape merge function to obtain 
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master networks for each patient. Sub-networks were then extracted for further visualization 
and analysis. 
Identification of putative AR and ERG target genes. A two-step approach was used. First, we 
collected sequenced read files (bed format) associated to public ChIP-seq assays targeting ERG 
in TMPRSS2-ERG positive human VCaP prostate cancer (GSM1328978, GSM1328979) and 
RWPE-1 normal prostate epithelium cells (GSM2195103, GSM2195106). BED Replicate files per 
cell-type were merged together prior performing peak calling (MACS 1.4; no model, 
shiftsize=150nts, p-value threshold: 1x10-5), followed by their genomic annotation to the closest 
transcription start sites (annoPeakR).  This analysis allowed to pair the characterized DEGs and 
mutated genes within the patient-derived networks with genes presenting proximal AR binding 
sites (<10 kb distance) on VCaP ChIP-seq profiles. This primary analysis has been validated in a 
second step by comparative visual inspection of ChIP-seq profiles. For this we used the 
qcGenomics platform (http://ngs-qc.org/qcgenomics/), in which the dedicated genome 
browser NAVi allows to visualize any publicly available ChIP-seq profile. Specifically, we used 
NAVi to extract all AR and ERG ChIP-seq profiles for TMPRSS2-ERG positive human VCaP 
prostate cancer and RWPE1 normal prostate epithelium cells. The pre-computed datasets were 
displayed simultaneously in the NAVi browser for comparative visualization. Only tracks with an 
apparent high signal-to-noise ratio were retained (VCaP-ERG: GSM2058880, GSM1328978, 
GSM1378979, GSM1328980, GSM1328981; VCaP-AR: GSM1410768, RWEP1-ERG: GSM927071, 
GSM2195110, GSM2195103; VCaP-GROseq: GSM2235682). Promoter-proximal ERG binding 
was scored positive in this visual 'validation' (attributing a yellow color to the respective nodes) 
only when there was a clearly visible peak above the background at a scale of 30 to 300 (read 
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count intensity; depending on the signal and noise intensities of each profile), provided that 
there was no other known TSS closer (see Extended Data Fig. 4 for examples of gain of ERG 
binding).  
Oligonucleotide sequences. Primers used for PCR are specified in Supplementary Table 5 of the 
Supplementary Information.  
Data availability. The RNA-seq data sets generated in the context of this study from 15 patient-
matched tumor and normal prostate tissue are available in the Gene Expression Omnibus (GEO) 
repository under the accession number GSE133626. The corresponding Exome-seq data sets 
from the prostates of the same 15 patients are available from the SRA database under the 
accession number [Data sets have been submitted, accession numbers will be provided when 
attributed]. Data sets for the pathway analysis shown in Extended Data Fig. 2 were downloaded 
from The Cancer Genome Atlas (TGCA) as described in the methods section. The sequencing 
statistics of RNA-seq and Exome-seq experiments are specified in Supplementary Table 4 of the 
Supplementary Information.  
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Extended data Fig. 1: Validation of four selected different types of mutations from
Exome-seq analysis using PCR coupled to Sanger sequencing. a, Single base deletion
in MGA gene in patient 5. b, Single base insertion in CFTR in patient 12. c, Missense
mutation in MST1R in patient 14 and d, Point mutation in RASSF8 in patient 13. Red
ovals highlight the regions of the mutations. Original (color-coded at the top) and
mutated sequences are depicted below each sequence for comparison.
All rights reserved. No reuse allowed without permission. 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/695999doi: bioRxiv preprint first posted online Jul. 11, 2019; 
Cadherin (140)
Wnt (280)
Integrin (157)
Inflammation by chemokine and cytokine (198)
Heterotrimeric G-protein-Gi α & Gs α (150)
Nicotinic acetylcholine receptor (90)
Cytoskeleton regulation by Rho GTPase (70)
TGF-beta (91)
PDGF (128)
Endothelin (72)
p53 (78)
Oxidative stress response(50)
Axon guidance by semaphorins (20)
FGF (109)
Adenine and hypoxanthine salvage (7)
De novo purine biosynthesis (27)
Cortocotropin releasing factor receptor (29)
5HT4 type receptor (30)
Ionotropic glutamate receptor (44)
Vitamin D metabolism (10)
Metabotropic glutamate receptor group III (64)
P53 feedback Loop 2 (47)
Angiogenesis (153)
Heterotrimeric G-protein-Gq α & Go α (108)
Plasminogen activating cascade (15)
Blood coagulation (38)
5-Hydroxy tryptamine degradation(18)
Synaptic vesicle trafficking (26)
Alpha adrenergic receptor (22)
Beta1 adrenergic receptor (42)
Notch (36)
Beta2 adrenergic receptor (42)
Histamine H1 receptor (42)
Metabotropic glutamate receptor group I (24)
Thyrotropin releasing hormone receptor (57)
Metabotropic glutamate receptor group II (45)
Adrenaline and noradrenaline biosynthesis (28)
Axon guidance by Slit/Robo (15)
FAS (35)
Axon guidance by netrin (26)
30
27
24
21
18
12
9
6
3
0
15
-l
o
g1
0 
(D
EG
 a
d
ju
st
ed
 p
-v
al
u
e)
Extended data Fig. 2: Heatmap showing enriched pathways using gene expression data from TCGA for prostate
cancer. Note that we selected only datasets for which PrCa with patient-matched normal tissue were available. P-
values corresponding to PANTHER-predicted alteration of pathway (left) are shown in color code (scale is shown on
the right of the table). TCGA codes for patients are given at the bottom.
All rights reserved. No reuse allowed without permission. 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/695999doi: bioRxiv preprint first posted online Jul. 11, 2019; 
dP4
c
P3
f
P7
e
P5
DEG Up DEG Down ERG target AR target ERG and AR targetDEG Up/Down
Mutation / DEG (Up/Down)Mutation Mutation  ERG TargetMutation Up
Additional ERG binding site(s) in VCaP not seen in RWPE1
a
Merged
b
P1
All rights reserved. No reuse allowed without permission. 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/695999doi: bioRxiv preprint first posted online Jul. 11, 2019; 
hP11
g
P8
j
P13
i
P12
l
P15
k
P14
Extended data Fig. 3: Patient-specific deregulations of Wnt pathway components for the indicated
patients (P). a, Merged network of all 15 patients used a background in (b) to (l). Frame and color codes are
shown below P5. b to l, deregulated and/or mutated components of the Wnt pathway in each patient.
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Extended data Fig. 4: AR binding and acquisition of ERG binding sites in VCaP prostate
cancer cells relative to RWPE-1 prostate epithelial cells. Screenshots of qcGenomics
(http://www.ngs-qc.org/qcgenomics/) browser NAVi displaying genes that show AR and/or
ERG binding in their promoter regions. a, HDAC1; b,WNT7B; c, SMARCCl; d, WNT2; e, FDZ8.
ChlP-seq data sets in a and b are from GEO accession numbers (from top to bottom)
GSM2058880 (AR, VCaP), GSM1328978 (ERG, VCaP) and GSM927071 (ERG, RWPE-1), as
specified. Note that in (a) ERG binding at the HDAC1 promoter is seen in VCaP and RWPE-1
cells, while in (b) for WNT7B a promoter-proximal ERG binding is seen in ‘normal’ RWPE-1
but not in VCaP cells; this ERG binding site is distant from the AR binding site. The ERG ChlP-
seq data sets in c, d and e are from GEO accession numbers (from top to bottom)
GSM927071 for RWPE-1, GSM1328978 for VCaP (both use anti-ERG antibody Epitomics
2805-1), GSM2195110 for RWPE-1 and GSM2086313 for VCaP. GSM2195110 was done by
using Anti-ERG Clone 9FY Biocare # CM421 C, GSM2195110 used an anti-ERG antibody but
did not provide the source. Note the consistency between corresponding experiments with
different antibodies.
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Extended data Fig. 5: Patient-specific deregulations
of the PDGF and EGFR pathway components for the
indicated patients (P). a, Merged network of 10
patients used a background in (b) to (l) for PDGF
pathway. j, Merged network of 7 patients used as a
background in (k) to (o) for EGFR pathway. Frame
and color codes are shown below P12. b to i,
deregulated and/or mutated components of the
PDGF pathway in each patient. k to o deregulated
and/or mutated components of EGFR pathway in
each patient.
i
P15
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Extended data Fig. 6: Patient-specific deregulations of the PDGF and EGFR pathway components
for the indicated patients (P). a, Network display of deregulated and mutated factors of patient P1
in the WNT, Angiogenesis and Cytokine Pathways to reveal connectivities between the different
pathways. b, Similar representation of the de-regulated and mutated factors in P2 for the WNT,
PDGF and EGFR pathways.
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